N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
100% efficacy against severe Covid-19 disease and hospitalizations
The first wave of shipments includes several countries, such as Germany, France and Austria
Circular revenues already at 16% of sales, driven by healthcare informatics and services to enhance medical equipment uptime and utilization, system and software upgrades for enhanced functionality and extended lifetime and reusing refurbished parts and systems
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
Zydus unveils its ‘innovation and care’ centric corporate brand identity
he financing was significantly oversubscribed with high demand from both existing and new investors.
Subscribe To Our Newsletter & Stay Updated
